Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study
Authors:
- Daniel Prieto-AlhambraDPDaniel Prieto-Alhambra
- Sonia ServitjaSSSonia Servitja
- M. Kassim JavaidMJM. Kassim Javaid
- Laia GarrigósLGLaia Garrigós
- Nigel K. ArdenNANigel K. Arden
- Cyrus CooperCCCyrus Cooper
- Joan AlbanellJAJoan Albanell
- Ignasi TusquetsITIgnasi Tusquets
- Adolfo Diez-PerezADAdolfo Diez-Perez
- Xavier NoguesXNXavier Nogues
- 21 March 2012
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 133 (3) , 1159-1167
Abstract
Aromatase inhibitor (AI)-related bone loss is associated with increased fracture rates. Vitamin D might play a role in minimising this effect. We hypothesised that 25-hydroxy-vitamin D concentrations [25(OH)D] after 3 months supplementation might relate to bone loss after 1 year on AI therapy. We conducted a prospective cohort study from January 2006 to December 2011 of a consecutive sample of women initiating AI for early breast cancer who were ineligible for bisphosphonate therapy and stayed on treatment for 1 year (N = 232). Serum 25(OH)D was measured at baseline and 3 months, and lumbar spine (LS) bone mineral density at baseline and 1 year. Subjects were supplemented with daily calcium (1 g) and vitamin D3 (800 IU) and additional oral 16,000 IU every 2 weeks if baseline 25(OH)D was 2 [0.012–0.024], P < 0.0001). Higher 25(OH)D at 3 months protected against LS bone loss (−0.5 % per 10 ng/ml [95 % CI −0.7 to −0.3 %], adjusted P = 0.0001), and those who reached levels ≥40 ng/ml had reduced bone loss by 1.70 % [95 % CI 0.4–3.0 %; adjusted P = 0.005] compared to those with low 25(OH)D levels (<30 ng/ml). We conclude that improved vitamin D status using supplementation is associated with attenuation of AI-associated bone loss. For this population, the current Institute of Medicine target recommendation of 20 ng/ml might be too low to ensure good bone health.Keywords
This publication has 36 references indexed in Scilit:
- Exemestane for Breast-Cancer Prevention in Postmenopausal WomenNew England Journal of Medicine, 2011
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology, 2010
- Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 TrialJournal of Clinical Oncology, 2008
- Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230Journal of Clinical Oncology, 2008
- A review of the BIG results: the Breast International Group 1–98 trial analysesThe Breast, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialThe Lancet, 2005
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancerThe Lancet, 2005